Glomerulonephritis – Current Treatment – Detailed, Expanded Analysis (US)
Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As more glomeruli become damaged, a progressive decline in renal function can occur, leading to chronic kidney disease (CKD). There are various types of glomerulonephritis, including immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and membranous nephropathy (MN). In the United States, these conditions are typically managed by nephrologists. With few approved drug treatments available, prescribers are required to consider various off-label immunosuppressive agents that may be able to limit the damage and inflammation in the glomeruli. The recent approval of GSK’s Benlysta (belimumab) and Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for LN may bring about a change not only in the treatment paradigm for this specific GN type but also more broadly for the indication.
How do nephrologists approach the management of patients with IgA nephropathy, FSGS, LN, or MN?
What percentage of GN patients are prescribed pharmacotherapy?
What are the key drug classes that nephrologists use to manage patients with GN? How are Benlysta and Lupkynis being incorporated into treatment models for LN?
What is the order of use of the key drug classes? Which drug class is most commonly used after failure of current therapy?
How does treatment differ between patients with IgA nephropathy, FSGS, LN, or MN?
Geography: United States
Primary research survey of 100 U.S. nephrologists
Key drugs / drug classes covered: Corticosteroids, antihypertensive agents, diuretics, alkylating agents, antiproliferative agents, calcineurin inhibitors, Rituxan, Benlysta, Lupkynis, Orencia, Velcade, Tavalisse, fish oil products, etc.
Key insights provided:
Factors influencing disease management and treatment decisions.
Drivers of treatment selection.
Physician-reported treatment practices and brand-level patient shares.
Rationale for changes in treatment approach.
Physician insight on persistency and compliance.
Physician-reported recent/anticipated changes in brand usage or treatment approach.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Glomerulonephritis - Current Treatment - Detailed, Expanded Analysis (US)
Current Treatment Physician Insights Glomerulonephritis US May 2021
Rohit Bansal, M.S. (Pharm.)
Rohit Bansal, M.S. (Pharm.), is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at DRG, part of Clarivate. He has authored several reports on metabolic indications, chiefly dyslipidemia and nonalcoholic steatohepatitis (NASH). Prior to joining DRG, he worked in a consultancy assisting various pharmaceutical companies. He earned his master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research (NIPER) in India.